Equillium (EQ) Competitors $0.39 +0.00 (+0.13%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. CNTX, RNXT, ANVS, PRLD, ADVM, ATNM, APLT, STTK, VRCA, and RENBShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Context Therapeutics (CNTX), RenovoRx (RNXT), Annovis Bio (ANVS), Prelude Therapeutics (PRLD), Adverum Biotechnologies (ADVM), Actinium Pharmaceuticals (ATNM), Applied Therapeutics (APLT), Shattuck Labs (STTK), Verrica Pharmaceuticals (VRCA), and Renovaro (RENB). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Context Therapeutics RenovoRx Annovis Bio Prelude Therapeutics Adverum Biotechnologies Actinium Pharmaceuticals Applied Therapeutics Shattuck Labs Verrica Pharmaceuticals Renovaro Context Therapeutics (NASDAQ:CNTX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Which has more risk and volatility, CNTX or EQ? Context Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CNTX or EQ? 14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 2.8% of Context Therapeutics shares are held by company insiders. Comparatively, 31.6% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend CNTX or EQ? Context Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 819.40%. Equillium has a consensus target price of $3.00, suggesting a potential upside of 676.20%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Context Therapeutics is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is CNTX or EQ more profitable? Context Therapeutics has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% Equillium -10.05%-20.68%-10.77% Does the media prefer CNTX or EQ? In the previous week, Context Therapeutics had 10 more articles in the media than Equillium. MarketBeat recorded 11 mentions for Context Therapeutics and 1 mentions for Equillium. Equillium's average media sentiment score of 1.87 beat Context Therapeutics' score of 1.23 indicating that Equillium is being referred to more favorably in the news media. Company Overall Sentiment Context Therapeutics Positive Equillium Very Positive Which has preferable earnings & valuation, CNTX or EQ? Equillium has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.31-2.11Equillium$30.41M0.45-$13.34M-$0.39-0.99 Does the MarketBeat Community prefer CNTX or EQ? Equillium received 8 more outperform votes than Context Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes2880.00% Underperform Votes720.00% EquilliumOutperform Votes3680.00% Underperform Votes920.00% SummaryEquillium beats Context Therapeutics on 9 of the 17 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.81M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-2.768.6727.2119.96Price / Sales0.45262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book0.606.597.074.69Net Income-$13.34M$143.75M$3.23B$248.14M7 Day Performance1.71%0.68%0.68%0.91%1 Month Performance1.15%11.93%9.59%5.71%1 Year Performance-50.80%4.33%32.02%14.71% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium3.181 of 5 stars$0.39+0.1%$3.00+676.2%-45.6%$13.81M$30.41M-2.7640Positive NewsGap UpHigh Trading VolumeCNTXContext Therapeutics3.1009 of 5 stars$0.59+1.9%$6.00+920.4%-67.4%$52.75MN/A-0.657Positive NewsGap UpRNXTRenovoRx2.9931 of 5 stars$1.42+1.4%$7.00+393.0%+16.2%$51.93M$240K-2.496Positive NewsShort Interest ↓High Trading VolumeANVSAnnovis Bio2.1282 of 5 stars$2.63+11.9%$34.75+1,221.3%-51.5%$51.25MN/A-0.593Analyst RevisionPRLDPrelude Therapeutics3.2668 of 5 stars$0.91+2.4%$4.00+341.0%-74.2%$51.22M$7M-0.51120Gap UpADVMAdverum Biotechnologies4.0007 of 5 stars$2.43+9.5%$26.40+986.4%-67.1%$50.77M$1M-0.41190Short Interest ↑Gap DownATNMActinium Pharmaceuticals1.2301 of 5 stars$1.62+5.2%$4.00+146.9%N/A$50.54M$81K-1.1730APLTApplied Therapeutics4.3005 of 5 stars$0.36+0.7%$6.10+1,614.0%-93.1%$50.39M$265K-0.2230Positive NewsSTTKShattuck Labs2.544 of 5 stars$1.05+3.5%$7.50+617.7%-83.9%$50.05M$4.61M-0.68100Positive NewsVRCAVerrica Pharmaceuticals4.4617 of 5 stars$0.54+9.3%$8.00+1,379.6%-92.1%$50.01M$7.18M-0.3040Positive NewsShort Interest ↓RENBRenovaro2.349 of 5 stars$0.29-6.4%N/A-73.5%$49.90MN/A-0.3120Positive News Related Companies and Tools Related Companies Context Therapeutics Competitors RenovoRx Competitors Annovis Bio Competitors Prelude Therapeutics Competitors Adverum Biotechnologies Competitors Actinium Pharmaceuticals Competitors Applied Therapeutics Competitors Shattuck Labs Competitors Verrica Pharmaceuticals Competitors Renovaro Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EQ Stock Free EQ Stock Alerts